Role of Booster Dose on Antibody Titer after Recombinant Hepatitis B Vaccination

The necessity of booster vaccination after neonatal hepatitis B vaccination

Soon after introducing recombinant hepatitis B virus (HBV) vaccine, universal neonatal vaccination became the corner stone of the preventive measures for this potentially life threatening infection (1-3). By 2006 more than 177 out of 193 member states of world health organization (WHO) introduced HBV vaccination in their national infant immunization programs (1). Following a complete series of ...

the necessity of booster vaccination after neonatal hepatitis b vaccination

بررسی دوام آنتی بادی anti-HBs و خاطره ایمنی واکسن هپاتیت B ، 18 سال پس از واکسیناسیون دوره نوزادی در دانشجویان دانشگاه تهران

Background The duration of infantile hepatitis B vaccination-induced immunity is still unknown. We assessed antibody persistence and immunological memory to hepatitis B 18 years after vaccination during infancy in Iranian young adults at risk of hepatitis B virus infection due to behavioral or occupational exposures. Methods This study was conducted on 395 freshman students of with a history of...

Seroconversion after hepatitis B vaccination in healthy young adults, and the effect of a booster dose.

OBJECTIVE Previous studies have shown that 5% to 15% of healthy people do not show a protective antibody response following hepatitis B vaccination. The study was done to determine the protective efficacy of vaccination in healthy young adults 1 to 4 years after the three dose vaccination series and to study the effect of a booster dose on non-responders and hypo-responders. DESIGN Prospectiv...

Hepatitis B virus antibody levels 7 to 9 years after booster vaccination in Alaska native persons.

Hepatitis B antibody persistence was assessed in individuals who had previously received a vaccine booster. We measured hepatitis B surface antigen antibody (anti-HBs) levels 7 to 9 years post-hepatitis B booster in individuals with primary vaccination at birth. While 95 (91.3%) of 104 participants had detectable anti-HBs (minimum, 0.1 mIU/ml; maximum, 1,029 mIU/ml), only 43 (41%) had protectiv...